Furthermore, the FOXA1-KDM6A-ARHGDIB axis has been identified as a critical pathway in bladder cancer metastasis, underscoring the therapeutic potential of targeting KDM6A in clinical settings. This evidence concerns the gene KDM6A and urinary bladder cancer.